MEK Inhibitor REC-4881 — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Phase2	Phase 2	1	1	0	3	0	—	—	2009-12

Computedclinicaltrialsci-drug-pipeline-v1Stage rules

Data updated 17 hours agoSource updated unknown

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF L597S1
MEK Inhibitor REC-4881

Clinical trials

Trials with this intervention (3)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–3 of 3 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05552755	Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP)(TUPELO)	recruiting	Phase 1 / Phase 2	67	Recursion Pharmaceuticals Inc.INDUSTRY	1	Jun 5, 2026	clinicaltrials
NCT06005974	A Study of REC-4881 in Participants With Cancers Which Have an AXIN1 or APC Mutation	terminated